Suggested remit: To appraise the clinical and cost effectiveness of deucravacitinib within its marketing authorisation for treating moderate to severe plaque psoriasis.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3859

Project Team

Project lead Daniel Davies

Email enquiries


Key events during the development of the guidance:

Date Update
23 February 2022 Invitation to participate
07 December 2021 - 20 January 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
16 July 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-February 2022 when we will write to you about how you can get involved.

For further information on our processes and methods, please see our CHTE processes and methods manual